| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-02 |
| filingDate |
2007-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a4dac91b3a4c18aa0abf810e2c19eeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cda696b52e326f1b3896bbc8bbc19f93 |
| publicationDate |
2010-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010093985-A1 |
| titleOfInvention |
Use of at least one cytosolic phospholipase a2 inhibitor as a medicine for symptomatic treatment of mucoviscidosis |
| abstract |
A subject of the invention is the use of at least one cytosolic phospholipase A2 (cPLA2) inhibitor in the preparation of a medicament intended for the preventive and/or curative symptomatic treatment of cystic fibrosis, particularly of the increased secretion of mucus in cystic fibrosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112312906-A |
| priorityDate |
2006-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |